Ischemia-Modified Albumin (IMA) Is Associated with Poor Survival in Patients with Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF): A Pilot Study

• Main Authors: Angelo Zinellu (Author), Stefano Zoroddu (Author), Simona Fois (Author), Sabrina Mellino (Author), Chiara Scala (Author), Erika Virdis (Author), Elisabetta Zinellu (Author), Salvatore Sotgia (Author), Panagiotis Paliogiannis (Author), Arduino A. Mangoni (Author), Ciriaco Carru (Author), Pietro Pirina (Author), Alessandro G. Fois (Author)
• Format: Book
• Published: MDPI AG, 2024-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

There are increasing efforts to better predict adverse outcomes for idiopathic pulmonary fibrosis (IPF). Our aim was to assess the prognostic potential of ischemia-modified albumin (IMA), an established circulating marker of ischemia and, more recently, oxidative stress, in a cohort of 56 IPF patien...